GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of non-peptide: what the trials say vs what this community says — 23 comments in the full submission. View in context.
335
c/orforglipron·submitted 9 months ago by u/farid_kuipers

non-peptide: what the trials say vs what this community says

Discussionbranch of 7 comments

Something I keep coming back to: non-peptide: what the trials say vs what this community says. Holding off on any opinion until phase 3 reports. That is not a satisfying position and it is the honest one. The analytical point, which this board keeps getting wrong by importing habits from the peptide side. For a…

Read the full submission and all 23 comments →

This branch

7 comments, started 9 months ago
u/the_poster_in_question_202623 points·9 months ago·edited

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

replysharereportpermalink
[removed]9 points·9 months ago

[removed by moderator]

replysharereportpermalink
u/batch_number_bertievetting6 points·9 months ago·edited

Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.

replysharereportpermalink
u/ines_lindqvist6 points·9 months ago

I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.

replysharereportpermalink
u/batch_number_bertievetting4 points·9 months ago

do not assume reconstitution intuitions apply, there is nothing to reconstitute

replysharereportpermalink
u/farid_kuipersOP1 point·9 months ago

Correction: that is the oral peptide product, which is a different thing entirely. This one is a small molecule.

replysharereportpermalink
u/tidy_vialdrawer_watch281 point·9 months ago·edited

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

replysharereportpermalink

← back to the whole thread

About c/orforglipron

The small-molecule oral: why a non-peptide agonist escapes the absorption problems of oral semaglutide, what the ATTAIN and ACHIEVE readouts showed, and what a pill with no refrigeration requirement would do to the entire supply conversation this site is built around.

21kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/orforglipron
c/orforglipron rules
  1. Small molecule, not a peptide. Purity discussion here is a different problem.
  2. Cite ATTAIN/ACHIEVE arms specifically when quoting numbers.
  3. Availability speculation must be flaired Speculation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/phase_two_peteu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →